scholarly journals The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

2015 ◽  
Vol 33 (4) ◽  
pp. 715-729 ◽  
Author(s):  
Auris O. Huen ◽  
Ellen J. Kim
2021 ◽  
Vol 156 ◽  
pp. S3-S4
Author(s):  
Gabor Dobos ◽  
Andreea Calugareanu ◽  
Laurence Michel ◽  
Maxime Battistella ◽  
Caroline Ram-Wolff ◽  
...  

2012 ◽  
Vol 132 (5) ◽  
pp. 1487-1496 ◽  
Author(s):  
Valentina Manfé ◽  
Edyta Biskup ◽  
Peter Johansen ◽  
Maria R. Kamstrup ◽  
Thorbjørn F. Krejsgaard ◽  
...  

Immunotherapy ◽  
2013 ◽  
Vol 5 (4) ◽  
pp. 427-433 ◽  
Author(s):  
Alessandro Pileri ◽  
Chiara Delfino ◽  
Vieri Grandi ◽  
Nicola Pimpinelli

2011 ◽  
Vol 12 (12) ◽  
pp. 1019-1022 ◽  
Author(s):  
Ronnie M. Abraham ◽  
Qian Zhang ◽  
Niels Odum ◽  
Mariusz A. Wasik

2012 ◽  
Vol 21 (12) ◽  
pp. 964-966 ◽  
Author(s):  
Ivan V. Litvinov ◽  
Thomas S. Kupper ◽  
Denis Sasseville

Blood ◽  
2013 ◽  
Vol 122 (6) ◽  
pp. 943-950 ◽  
Author(s):  
Thorbjørn Krejsgaard ◽  
Ivan V. Litvinov ◽  
Yang Wang ◽  
Lixin Xia ◽  
Andreas Willerslev-Olsen ◽  
...  

Key Points The Jak/Stat3 pathway promotes the expression of IL-17F in malignant CTCL cells. IL-17F is highly expressed in a subset of CTCL patients and associated with progressive disease.


2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Maria Abreu ◽  
Marta Miranda ◽  
Mafalda Castro ◽  
Iolanda Fernandes ◽  
Renata Cabral ◽  
...  

The itch associated with cutaneous T-cell lymphoma (CTCL), including Mycosis Fungoides (MF) and Sézary syndrome (SS), is often severe and poorly responsive to treatment with antihistamines. Recent studies have highlighted the possible role of interleukins in nonhistaminergic itch. We investigated the role of IL-31 and IL-8 in CTCL, concerning disease severity and associated itch. Serum samples of 27 patients with CTCL (17 MF and 10 SS) and 29 controls (blood donors) were analyzed for interleukin- (IL-) 31 and IL-8; correlations with disease and itch severity were evaluated. IL-31 serum levels were higher in CTCL patients than in controls and higher in SS than in MF. Also, serum IL-31 levels were higher in patients with advanced disease compared to those with early disease, and they correlated positively with lactate dehydrogenase and beta 2-microglobulin levels, as well as with the Sézary cell count. Itch affected 67% of CTCL patients (MF: 47%; SS: 100%). Serum IL-31 levels were higher in itching patients than in controls and in patients without itching. There was no association between serum IL-8 and disease severity, nor with itching. Serum IL-8 levels correlated positively with peripheral blood leukocyte and neutrophil counts in CTCL patients. Our study suggests a role for IL-31 in CTCL-associated itch, especially in advanced disease and SS, offering a rational target for new therapeutic approaches. Increased serum IL-8 observed in some patients may be related to concomitant infections, and its role in exacerbating itch by recruiting neutrophils and promoting the release of neutrophil proteases deserves further investigation.


Sign in / Sign up

Export Citation Format

Share Document